fluoxetine has been researched along with bay 63-2521 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allanore, Y; Avouac, J; Becker, M; Clements, P; Cutolo, M; Czirjak, L; Damjanov, N; Del Galdo, F; Denton, CP; Distler, JHW; Distler, O; Figelstone, K; Foeldvari, I; Fransen, J; Frerix, M; Furst, DE; Guiducci, S; Herrick, AL; Hunzelmann, N; Khanna, D; Kowal-Bielecka, O; Kulak, A; Matucci-Cerinic, M; Müller-Ladner, U; Riemekasten, G; Silver, R; Smith, V; Sulli, A; Tarner, I; Tyndall, A; Valentini, G; van den Hoogen, F; van Laar, JM; Walker, UA; Welling, J; Wigley, F; Zulian, F | 1 |
1 review(s) available for fluoxetine and bay 63-2521
Article | Year |
---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; Fingers; Fluoxetine; Gastrointestinal Diseases; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Kidney Diseases; Lung Diseases; Phosphodiesterase 5 Inhibitors; Prostaglandins I; Pyrazoles; Pyrimidines; Raynaud Disease; Rheumatology; Scleroderma, Systemic; Selective Serotonin Reuptake Inhibitors; Ulcer | 2017 |